MAPT and Alzheimer disease: Microfluidic devices offer an ideal platform to study neuronal connectivity and spread of Tau pathology, and the number of publications appeared in recent years (7, 23, –, 28, 37) supports their utility as an in vitro model of AD to test intervention against neuronal cell death with loss of synapses and neuronal network, which is one of the main pathophysiological characteristics of AD.